Company intelligence / Profile preview

Smithers Viscient

Wareham, Massachusetts, United Statessmithers.com ↗

Ownership: Private
Development stage: Other

Overview

Smithers Viscient was a division of Smithers providing preclinical discovery and development services including safety assessments primarily to chemical and pharmaceutical industries. In 2019 the toxicology service unit was sold to Bioanalytical Systems Inc. (BASi). The "Viscient" branding has since been retired as part of a global rebranding under the unified "Smithers" name.

Industry: Contract Research Organization

Partnerships

Toxicology business sold to Bioanalytical Systems Inc. ("BASi") in May 2019

Beyond the preview

Go deeper on Smithers Viscient.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Smithers Viscient.

Explore the full profile